LILLY's TAZIDIME (CEFTAZIDIME) LAUNCH SET FOR FIRST WEEK IN DECEMBER FOLLOWING NOV. 20 APPROVAL; REP. WAXMAN SAYS ANTIBIOTICS ARE NOT ELIGIBLE FOR EXCLUSIVITY